DUPIXENT
Dupixent (dupilumab) is a prescription, injectable biologic medicine approved to treat moderate-to-severe eczema, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and COPD by blocking specific proteins (IL-4, and IL-13) that cause inflammation. It is not a steroid or immunosuppressant but acts on the immune system to reduce inflammation.The following work is HCP-focused materials and congress pieces.
1 million patients - video
Video presented at the European Respiratory Society (ERS) Congress—the world’s largest annual gathering for respiratory professionals. This video celebrates the milestone of DUPIXENT being prescribed to 1 Million patients worldwide, and also announcing the approval for the treatment of Chronic Obstructive Pulmonary Disorder (COPD).
a million firsts - video
Video with interviews from Sanofi and Regeneron senior executives, patient testimonials, and healthcare professionals celebrating the renewed “firsts” that patients can get to experience again thanks to DUPIXENT. The A Million Firsts campaign involved celebrations throughout Sanofi and Regeneron that included townhalls, a 5K road race, among various activities for all those who are and were involved in providing these patients with a million firsts.
Reprint carrier
Patient Profile
cinemagraph wall - aad 2025
Cinemagraph wall presented at the American Academy of Dermatology (AAD) 2025 congress, showcasing the No Wonder it’s Possible campaign for DUPIXENT’s dermatologic indications. With subtle motion and transitions, we shuffle through the globally approved indications for DUPIXENT in dermatology (atopic dermatitis and prurigo nodularis).
Digital PAtient Profile DAta PAnel - aad 2025
Interactive patient profile data panel presented at the American Academy of Dermatology (AAD) 2025 congress. It showcases the No Wonder it’s Possible campaign for DUPIXENT’s dermatologic indications as a screen saver that comes up after 30 seconds of inactivity. Once the home screen is tapped, the user can shuffle through patient profiles, trial designs, efficacy, and other data pertaining to the globally approved indications for DUPIXENT in dermatology (atopic dermatitis and prurigo nodularis).
